67 Meta-analysis and systematic review of coronary vasospasm in ANOCA patients Mean age (years) ±SD or IQR Female n (%) Control group Diagnostic agent Diagnosis spasm Dosages 55.3±12.4 3187 (54.1) NA Ach >70% spasm, without additional criteria 2,20,100,200 ug 1 min ic into LAD 56 (IQR 46-63) 148 (15.0) NA Ergo >90% spasm, symptoms or ischemic ECG 20,40,80mg ic into LAD 61.6±9.2 40 (59.7) AP Ach >90% spasm, without additional criteria 10,30,100 ug 30s ic into LAD 63 (IQR 54-68) 59 (50.4) NA Ach >75% spasm, without additional criteria 10,30,100 ug 30s ic into LAD 61.4 153 (46.5) NA Ach >90% spasm, symptoms or ischemic ECG 20,50,100 ug 20s ic into LAD 65.5 28 (43.1) HC Ach >90% spasm, symptoms or ischemic ECG 20,50,100 ug 20s ic into LAD 60.2± 13.3 82 (41.4) NA Ach >90% spasm & ischemic ECG 20,50,100 ug 20s ic into LAD 63.0± 11.0 776 (47.4) NA Ach >75% spasm & ischemic ECG 20,50,100 ug 20s ic into LAD 63.2±12.3 74 (39.5) NA Ach >90% spasm, symptoms & ischemic ECG 20,50,100 ug 20s ic into LAD 64.4±10.8 193 (46.3) NA Ach >99% spasm, without additional criteria 20,50,100 ug 20s ic into LAD 55.5 76 (21.7) NA Ergo >75% spasm, without additional criteria 0.1, 0.2, mg iv 59.8 69 (52.7) NA Ach >75% spasm, without additional criteria 10,30,100 ug 30s ic into LAD 61.3 24 (48.0) NA Ach >90% spasm, symptoms & ischemic ECG 20,50,100 ug 30s ic into LAD 4
RkJQdWJsaXNoZXIy MTk4NDMw